Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Trial end date:
2023-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic
agent in the current treatment landscape where subjects with systemic lupus erythematosus
(SLE) have ongoing disease activity despite treatment with standard of care therapies.